SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from Pasithea Therapeutics Corp. (KTTA, KTTAW) (CIK 0001841330) (KTTA) — Nov 19, 2025

Pasithea Therapeutics Corp. (KTTA, KTTAW) (CIK 0001841330)
Date: Nov. 19, 2025 · CIK: 0001841330 · Accession: 0001213900-25-112467

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-291611

Date
November 19, 2025
Author
Dr. Tiago Reis Marques
Form
CORRESP
Company
Pasithea Therapeutics Corp. (KTTA, KTTAW) (CIK 0001841330)

Letter

Re: Pasithea Therapeutics Corp. (the "Company")

November 19, 2025

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Registration Statement on Form S-1 (File No. 333-291611)

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the "Registration Statement") be declared effective by the Securities and Exchange Commission at 5:15 p.m., Eastern Time, on November 20, 2025, or as soon as practicable thereafter.

The Company hereby authorizes James B. O'Grady of Lowenstein Sandler LLP, the Company's outside legal counsel, to orally modify or withdraw this request for acceleration.

Please call Mr. O'Grady of Lowenstein Sandler LLP at (646) 414-6849 to confirm the effectiveness of the Registration Statement or with any questions.

Very truly yours,
PASITHEA THERAPEUTICS CORP.

Show Raw Text
CORRESP
 1
 filename1.htm

 November 19, 2025

 VIA EDGAR

 United States Securities and Exchange Commission

 Division of Corporation Finance

 100 F Street, N.E.

 Washington, D.C. 20549

 Re:
 Pasithea Therapeutics Corp. (the "Company")

 Registration Statement on Form S-1 (File No. 333-291611)

 Ladies and Gentlemen:

 In accordance with Rule 461 under the Securities Act of 1933, as amended,
the Company hereby requests that the above-referenced Registration Statement (the "Registration Statement") be declared effective
by the Securities and Exchange Commission at 5:15 p.m., Eastern Time, on November 20, 2025, or as soon as practicable thereafter.

 The Company hereby authorizes James B. O'Grady of Lowenstein Sandler LLP, the Company's outside legal counsel, to orally modify
or withdraw this request for acceleration.

 Please call Mr. O'Grady of Lowenstein Sandler LLP at (646)
414-6849 to confirm the effectiveness of the Registration Statement or with any questions.

 Very truly yours,

 PASITHEA THERAPEUTICS CORP.

 By:
 /s/ Dr. Tiago Reis Marques

 Dr. Tiago Reis Marques

 Chief Executive Officer